Allo-EBT: EBV-specific T cells to treat PTLD (Phase I/II Trial)

Safety evaluation of allogeneic HLA-matched EBV-specific T cells (EBV-CTLs) in children and adults with advanced EBV-associated post-transplant malignancies (PTLD and soft tissue tumors)

Sponsor:

Hannover Medical School
Carl-Neuberg-Strasse 1
30625 Hannover

Principal Coordinating Investigator:

Prof. Dr. med. Britta Maecker-Kolhoff
Pediatric Hematology and Oncology
Hannover Medical School
Carl-Neuberg-Strasse 1
30625 Hannover

Trial protocol code: allo-EBT

Clinical Trials.gov: n.a.

EudraCT number: 2022-001196-13

Publications:

Combined treatment with allogeneic Epstein-Barr- and human polyomavirus 1 specific T-cells in progres-sive multifocal leukoencephalopathy and EBV infection: a case report.
Nay S, Möhn N, Grote-Levi L, Bonifacius A, Saßmann ML, Karacondi K, Tischer-Zimmermann S, Pöter H, Mahmoudi N, Wattjes MP, Maecker-Kolhoff B, Höglinger G, Eiz-Vesper B, Skripuletz T. Ther Adv Neurol Disord. 2024 May 28;17:17562864241253917. doi: 10.1177/17562864241253917.

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.
Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft HG, Arseniev L, Beier R, Beutel G, Cario G, Fröhlich B, Greil J, Hansmann L, Hasenkamp J, Höfs M, Hundsdoerfer P, Jost E, Kafa K, Kriege O, Kröger N, Mathas S, Meisel R, Nathrath M, Putkonen M, Ravens S, Reinhardt HC, Sala E, Sauer MG, Schmitt C, Schroers R, Steckel NK, Trappe RU, Verbeek M, Wolff D, Blasczyk R, Eiz-Vesper B, Maecker-Kolhoff B. J Clin Invest. 2023 Jun 15;133(12):e163548. doi: 10.1172/JCI163548.

Adoptive Cell Transfer of Allogeneic Epstein-Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report.
Hansen BT, Bacher P, Eiz-Vesper B, Heckl SM, Klapper W, Koch K, Maecker-Kolhoff B, Baldus CD, Fransecky L. Front Immunol. 2021 Dec 3;12:727814. doi: 10.3389/fimmu.2021.727814.

Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients.
Schulze Lammers FC, Bonifacius A, Tischer-Zimmermann S, Goudeva L, Martens J, Lepenies B, von Karpowitz M, Einecke G, Beutel G, Skripuletz T, Blasczyk R, Beier R, Maecker-Kolhoff B, Eiz-Vesper B. J Clin Immunol. 2022 Apr;42(3):546-558. doi: 10.1007/s10875-021-01205-1. Epub 2022 Jan 6.

Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Com-bined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes.
Mika T, Strate K, Ladigan S, Aigner C, Schlegel U, Tischoff I, Tischer-Zimmermann S, Eiz-Vesper B, Maecker-Kolhoff B, Schroers R. Front Med (Lausanne). 2019 Dec 18;6:295. doi: 10.3389/fmed.2019.00295.

Dissecting Epstein-Barr Virus-Specific T-Cell Responses After Allogeneic EBV-Specific T-Cell Transfer for Central Nervous System Posttransplant Lymphoproliferative Disease.
Schultze-Florey RE, Tischer S, Kuhlmann L, Hundsdoerfer P, Koch A, Anagnostopoulos I, Ravens S, Goudeva L, Schultze-Florey C, Koenecke C, Blasczyk R, Koehl U, Heuft HG, Prinz I, Eiz-Vesper B, Maecker-Kolhoff B. Front Immunol. 2018 Jun 27;9:1475. doi: 10.3389/fimmu.2018.01475.

Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.
Tischer S, Priesner C, Heuft HG, Goudeva L, Mende W, Barthold M, Kloeß S, Arseniev L, Aleksandrova K, Maecker-Kolhoff B, Blasczyk R, Koehl U, Eiz-Vesper B. . J Transl Med. 2014 Dec 16;12:336. doi: 10.1186/s12967-014-0336-5.

EBV-specific T-cell immunity in pediatric solid organ graft recipients with posttransplantation lymphoproliferative disease.
Wilsdorf N, Eiz-Vesper B, Henke-Gendo C, Diestelhorst J, Oschlies I, Hussein K, Pape L, Baumann U, Tönshoff B, Pohl M, Höcker B, Wingen AM, Klapper W, Kreipe H, Schulz TF, Klein C, Maecker-Kolhoff B. Transplantation. 2013 Jan 15;95(1):247-55. doi: 10.1097/TP.0b013e318279968d.